Project description
Cutting-edge tools for preventing atrial fibrillation, strokes
Atrial fibrillation (AF) and stroke are major health care problems in Europe. They are most often the clinical expression of atrial cardiomyopathy, which is under-recognised due to the lack of specific diagnostic tools. Multidisciplinary research and stratified approaches are urgently needed to preempt the AF-related threat to healthy ageing in Europe. EU-funded MAESTRIA is a consortium of clinicians, scientists and pharma industrials who are at the forefront of research and medical care of AF and stroke patients. It will create multi-parametric digital tools based on a new generation of biomarkers that integrate artificial intelligence processing and big data from cutting edge imaging, electrocardiography and omics technologies. It will develop novel diagnostic tools and personalised therapies for AF.
Objective
Atrial fibrillation (AF) and stroke are major health care problems in Europe. They are most often the clinical expression of atrial cardiomyopathy, which is under-recognised due to the lack of specific diagnostic tools. Multidisciplinary research and stratified approaches are urgently needed to prevent, diagnose, and treat AF and stroke and preempt the AF-related threat to healthy ageing in Europe. MAESTRIA is a European consortium of 18 clinicians, scientists and Pharma industrials who are at the forefront of research and medical care of AF and stroke patients. It will create multi-parametric digital tools based on a new generation of biomarkers that integrate artificial intelligence (AI) processing and big data from cutting edge imaging, electrocardiography and omics technologies. It will develop novel biomarkers, diagnostic tools and personalized therapies for atrial cardiomyopathy. Digital Twin technologies, a rich data integrator combining biophysics and AI will be used to generate virtual twins of the human atria using patient-specific data. Unique experimental large-animal models, ongoing patient cohorts and a prospective MAESTRIA cohort of patients will provide rigorous validation for new biomarkers and newly developed tools. A dedicated core lab will collect and homogenize clinical data. MAESTRIA will be organized as a user-centered platform, easily accessible via clinical parameters routinely used in European hospitals. A Scientific Advisory Board comprising potential clinician users will help MAESTRIA meet clinical and market needs. Dissemination and visibility of the MAESTRIA consortium mission will benefit from participation of the German Competence Network on Atrial Fibrillation (AFNET), and support from the European Society of Cardiology, clinicians, scientists, and other professional societies. MAESTRIA will be ready to tackle the major challenges of data integration and personalized medicine focused on atrial cardiomyopathy, AF and stroke.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
75006 Paris
France
See on map
Participants (19)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
75013 Paris
See on map
75012 Paris
See on map
OX1 2JD Oxford
See on map
B15 2TT Birmingham
See on map
48149 Muenster
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
33098 Paderborn
See on map
45147 Essen
See on map
6200 MD Maastricht
See on map
10561 Athina
See on map
28029 Madrid
See on map
02114 Boston Ma
See on map
91120 Palaiseau
See on map
J1J 3H5 Sherbrooke
See on map
91052 Erlangen
See on map
OX2 0HP Oxford
See on map
75009 PARIS
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
28002 Madrid
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
07743 Jena
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
6229 EV Maastricht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.